Evidence map›Paper›PMID 37046304›Full record

ArticlePediatric rheumatology online journal2023

Distinct phenotypes of multisystem inflammatory syndrome in children: a cohort study.

Thomas Renson, Nils D Forkert, Kimberly Amador, Paivi Miettunen, Simon J Parsons, Muhammed Dhalla, Nicole A Johnson, Nadia Luca, Heinrike Schmeling, Rebeka Stevenson and 3 more

Open access · goldAbstract read
In one paragraph

Article in Pediatric rheumatology online journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Thomas RensonRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. thomas.renson@uzgent.be.ORCID http://orcid.org/0000-0002-5503-000X
Nils D ForkertDepartment of Radiology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Kimberly AmadorDepartment of Radiology, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Paivi MiettunenRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.
Simon J ParsonsCritical Care Medicine, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Muhammed DhallaRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.
Nicole A JohnsonRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.
Nadia LucaRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.
Heinrike SchmelingRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.
Rebeka StevensonRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.
Marinka TwiltRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.
Lorraine HamiwkaNephrology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.
Susanne BenselerRheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultisystem inflammatory syndrome in children (MIS-C) is a severe disease with an unpredictable course and a substantial risk of cardiogenic shock. Our objectives were to (a) compare MIS-C phenotypes across the COVID-19 pandemic, (b) identify features associated with intensive care need and treatment with biologic agents.

methodsYouth aged 0-18 years, fulfilling the World Health Organization case definition of MIS-C, and admitted to the Alberta Children's Hospital during the first four waves of the COVID-19 pandemic (May 2020-December 2021) were included in this cohort study. Demographic, clinical, biochemical, imaging, and treatment data were captured.

resultsFifty-seven MIS-C patients (median age 6 years, range 0-17) were included. Thirty patients (53%) required intensive care. Patients in the third or fourth wave (indicated as phase 2 of the pandemic) presented with higher peak ferritin (µg/l, median (IQR) = 1134 (409-1806) vs. 370 (249-629), P = 0.001), NT-proBNP (ng/l, median (IQR) = 12,217 (3013-27,161) vs. 3213 (1216-8483), P = 0.02) and D-dimer (mg/l, median (IQR) = 4.81 (2.24-5.37) vs. 2.01 (1.27-3.34), P = 0.004) levels, and higher prevalence of liver enzyme abnormalities (n(%) = 17 (68) vs. 11 (34), P = 0.02), hypoalbuminemia (n(%) = 24 (100) vs. 25 (81), P = 0.03) and thrombocytopenia (n(%) 18 (72) vs. 11 (34), P = 0.007) compared to patients in the first two waves (phase 1). These patients had a higher need of non-invasive/mechanical ventilation (n(%) 4 (16) vs. 0 (0), P = 0.03). Unsupervised clustering analyses classified 47% of the patients in the correct wave and 74% in the correct phase of the pandemic. NT-proBNP was the only significant contributor to the need for intensive care in all applied multivariate regression models. Treatment with biologic agents was significantly associated with peak CRP (mg/l (median, IQR = 240.9 (132.9-319.4) vs. 155.8 (101.0-200.7), P = 0.02) and ferritin levels (µg/l, median (IQR) = 1380 (509-1753) vs. 473 (280-296)).

conclusionsMIS-C patients in a later stage of the pandemic displayed a more severe phenotype, reflecting the impact of distinct SARS-CoV-2 variants. NT-proBNP emerged as the most crucial feature associated with intensive care need, underscoring the importance of monitoring.

Indexed as

COVID-19Cohort StudiesFerritinsHumansPandemicsSARS-CoV-2Systemic Inflammatory Response SyndromeFerritinsCardiogenic shockCOVID-19MIS-CPediatric intensive carePhenotypes

Identifiers

PMID37046304
PMCPMC10092941
OpenAlexW4365150699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.